INSP:NYE-Inspire Medical Systems Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 211.05

Change

+8.57 (+4.23)%

Market Cap

USD 6.35B

Volume

0.50M

Analyst Target

USD 81.10
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+1.58 (+1.41%)

USD 198.37B
MDT Medtronic PLC

+0.71 (+0.79%)

USD 115.25B
STE STERIS plc

+3.49 (+1.46%)

USD 23.57B
ZBH Zimmer Biomet Holdings Inc

-0.27 (-0.25%)

USD 22.04B
SNN Smith & Nephew SNATS Inc

+0.02 (+0.06%)

USD 13.37B
GMED Globus Medical

+0.93 (+1.32%)

USD 9.55B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.22B
BIO Bio-Rad Laboratories Inc

+2.81 (+0.85%)

USD 9.22B
PEN Penumbra Inc

+2.76 (+1.44%)

USD 7.80B
GKOS Glaukos Corp

+1.99 (+1.55%)

USD 7.05B

ETFs Containing INSP

PSCH Invesco S&P SmallCap Heal.. 4.06 % 0.29 %

+0.53 (+0.83%)

USD 0.20B
FDOC:LSE Fidelity Digital Health U.. 3.18 % 0.00 %

+0.03 (+0.83%)

USD 3.02M
XHE SPDR® S&P Health Care Eq.. 1.82 % 0.35 %

+0.67 (+0.83%)

USD 0.22B
QSML WisdomTree U.S. SmallCap .. 0.77 % 0.00 %

+0.06 (+0.83%)

USD 1.31M

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.75% 53% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.75% 50% F 27% F
Trailing 12 Months  
Capital Gain 8.36% 47% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.36% 47% F 26% F
Trailing 5 Years  
Capital Gain 275.87% 94% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 275.87% 94% A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 39.69% N/A N/A 92% A
Dividend Return 39.69% N/A N/A 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 76.52% N/A N/A 11% F
Risk Adjusted Return 51.87% N/A N/A 68% D+
Market Capitalization 6.35B 64% D 79% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.